

5-20-2013

## Oral Cancer Risk and Vitamin D Status, Intake and Supplementation: A Review

Karl Kingsley

*University of Nevada, Las Vegas*

C. Bergman

*University of Nevada, Las Vegas*

M. Keiserman

*University of Medicine and Dentistry of New Jersey*

Follow this and additional works at: [https://digitalscholarship.unlv.edu/dental\\_fac\\_articles](https://digitalscholarship.unlv.edu/dental_fac_articles)

---

### Repository Citation

Kingsley, K., Bergman, C., Keiserman, M. (2013). Oral Cancer Risk and Vitamin D Status, Intake and Supplementation: A Review. *Open Access Cancer*, 1(1), 1-5.

[https://digitalscholarship.unlv.edu/dental\\_fac\\_articles/52](https://digitalscholarship.unlv.edu/dental_fac_articles/52)

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Dental Medicine Faculty Publications by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact [digitalscholarship@unlv.edu](mailto:digitalscholarship@unlv.edu).

# Oral cancer risk and vitamin D status, intake and supplementation: A review

K Kingsley<sup>1\*</sup>, C Bergman<sup>2</sup>, M Keiserman<sup>3</sup>, C Mobley<sup>1</sup>

## Abstract

### Introduction

Vitamin D sufficiency is associated with a variety of human health benefits, while vitamin D deficiency has been identified as a potential risk factor for several health-related issues, including oral cancer. The goal of this critical review was to assess the research, epidemiologic evidence and mechanisms through which vitamin D may influence oral cancer risk or progression.

### Discussion

Recent evidence now suggests that vitamin D exhibits several different effects on normal and cancerous cells, including up-regulation of anti-proliferation and proapoptotic factors, as well as inhibition of cell-cycle promoters and growth factor signalling pathways, such as Wnt and mitogen-activated protein kinase (MAPK). Some studies, however, have demonstrated inconclusive results, which may be complicated by inadequate study design to account for baseline vitamin D status or deficiencies, and also by tumour-specific up-regulation of the vitamin D catabolism enzyme, cytochrome p450 24

(CYP24), or mutations in the vitamin D receptor (VDR), which have been observed in some oral cancers.

### Conclusion

This comprehensive analysis of research regarding vitamin D status, intake and metabolism suggests oral cancer risk may, in fact, be more interconnected than previously acknowledged. Furthermore, more in-depth analysis of VDR and CYP24 expression, along with baseline vitamin D status, may elucidate some of the underlying mechanisms of oral cancer responsiveness, which may be useful to oral oncologists, oral health care providers and oral epidemiologists as they strive to improve patient health and outcomes.

## Introduction

### Oral cancer

Although the rates of oral cancer incidence and mortality have declined in the United States and other industrialized countries over recent decades, concomitant increases have been observed in other nations and worldwide, in general<sup>1,2</sup>. As workplace participation and social mobility have increased along with disposable incomes in developing economies, the availability of tobacco and alcohol products has been associated with increasing rates of oral cancers<sup>2-5</sup>. Studies of the primary risk factors for the development of oral cancers in the United States have found that tobacco use and, to a lesser extent, alcohol consumption, when combined, may be responsible for as much as 80% of this cancer risk<sup>2,4,6</sup>.

However, these studies have also uncovered differing incidence and mortality rates among demographic subgroups within the population,

including stark differences by age, sharp increases observed among females and much higher rates observed among minorities<sup>7-13</sup>. An additional important risk factor for oral and pharyngeal cancers (OPCs) is oral infection with the human papillomavirus (HPV)<sup>1,11</sup>. Oral HPV infection may be disproportionately associated with specific demographic subgroups, such as men and some minority subgroups, which may underlie some of the divergent geospatial and geographic OPC trends observed<sup>12,14</sup>.

### Dietary influences

Although the majority of OPC risk in developed countries may be attributable to tobacco and alcohol consumption or HPV infection, several studies have recently demonstrated that opposing, health-protective effects and reduced incidence of OCP may be associated with intake of specific dietary components such as coffee, fibre, folic acid and the vitamins A, C, D and E<sup>15,16</sup>. In fact, recent meta-analyses have demonstrated consistent, inverse associations between the intake of specific dietary components, such as folate, and the risk, development and progression of OCP<sup>17,18</sup>. In addition, dietary limitations or restrictions and micronutrient deficiencies have been shown to increase OCP risk<sup>15-17</sup>. It is difficult (and often problematic) to distinguish the effects of specific micronutrients or constituents in dietary intake studies from those of the foods that contain them<sup>16</sup>. This may explain why researchers have concluded that dietary intake (but not specific vitamins or micronutrients) accounts for as much as 20–25% of the variability in OCP risk<sup>15,16</sup>.

\*Corresponding author  
Email: Karl.Kingsley@unlv.edu

<sup>1</sup> Department of Biomedical Sciences, School of Dental Medicine, University of Nevada, Las Vegas, 1001 Shadow Lane, Las Vegas, Nevada, 89106, USA

<sup>2</sup> Department of Food and Beverage, Harrah Hotel College, University of Nevada, Las Vegas, 4505 Maryland Parkway, Las Vegas, Nevada, 89154, USA

<sup>3</sup> Department of Nutritional Sciences, University of Medicine and Dentistry of New Jersey, 65 Bergen St 149, Newark, New Jersey, 07107, USA

## Vitamin D

Large-scale population studies have revealed that low serum vitamin D levels are associated with significant increases in cancer risk<sup>19,20</sup>. More specifically, epidemiologic and case-controlled studies have now demonstrated that low vitamin D levels are strongly associated with OPC risk<sup>21,22</sup>. In fact, more recent evidence now demonstrates that OPC patients are more likely to harbour vitamin D receptor (VDR) gene polymorphisms, mutations or deletions<sup>23-25</sup>. Conversely, those with specific VDR mutations were at higher risk for developing OPC than those with normal genotypes<sup>26-28</sup>.

Vitamin D<sub>3</sub> precursors are produced in the skin upon exposure to sunlight, but also may be ingested from dietary sources, such as animal food products, while vitamin D<sub>2</sub> may be obtained from plant-based products and synthetically manufactured dietary additives or nutritional supplements<sup>29,30</sup>. No significant differences between the metabolism of the major circulating forms, vitamin D<sub>2</sub> [25(OH)D<sub>2</sub>] and vitamin D<sub>3</sub> [25(OH)D<sub>3</sub>] have been noted, with vitamin D precursors either from sun exposure or from diet hydroxylated in the liver via the p450 27A system to 25-hydroxyvitamin D [25(OH)D]<sup>30</sup>. The circulating concentration of 25(OH)D ranges between 20 and 150 nmol/l (9 and 60 ng/ml), which has a normal serum half-life of about 3 weeks, with vitamin D intoxication described at concentrations above 375 nmol/l (150 ng/ml)<sup>31</sup>.

Although the primary site for vitamin D metabolism is hydroxylation in the hepatic p450 27A system, the kidney, bones and parathyroid gland are major sites of additional processing of 25(OH)D to the active form 1,25-dihydroxy vitamin D [1,25(OH)<sub>2</sub>D] via the p450 27B system, which is also involved in both calcium and phosphorous homeostasis<sup>30,31</sup>. The normal human serum range for the active form,

1,25(OH)<sub>2</sub>D, is between 38 and 144 pmol/l (16 and 60 pg/ml) that has a circulation half-life between 4 and 6 hours<sup>30,31</sup>. Vitamin D doses may also be stated in international units (IU), which adjusts for biological activity or effect with one IU of vitamin D defined as the activity of 0.025 µg of 1,25(OH)<sub>2</sub>D<sub>3</sub><sup>29</sup>. The simplest way to understand and compare the varying studies of vitamin D may be to apply the conversion of IU to grams of 1,25(OH)<sub>2</sub>D<sub>3</sub>; 40 IU equals 1 µg in dietary sources, and to apply the conversion of clinical serum levels to *in vitro* concentrations, 2.5nmol/l equals 1 ng/ml<sup>30</sup>.

Although vitamin D is routinely supplemented into dietary food staples of developed countries, the primary determinant of vitamin D status for the developing world is sun exposure, since vitamin D production in the skin is proportional to ultraviolet (UV) light exposure<sup>32</sup>. For instance, although an eight ounce glass of milk in the United States is fortified to contain 100 IU of vitamin D, exposure of the skin to enough UV-B radiation to cause a slight pinkness in Caucasian skin produces the equivalent to an oral dose of 20,000 IU of vitamin D<sup>20,32</sup>. These findings may explain the epidemiologic observations that increased sun exposure in certain geographic regions and among certain populations was associated with reduced cancer mortality and risk at all tumour sites. Data from more than 100 countries have demonstrated strong, inverse correlations between solar UVB exposure for 15 types of cancer and significant (although less robust) effects observed among nine other cancers, including those of the larynx and oral cavity/pharynx<sup>19-22,32,33</sup>.

Based upon this information, the primary objective of this study is to provide a critical review of not only the research and epidemiologic evidence but also the mechanisms through which vitamin D may influence OPC risk and progression.

## Discussion

The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964), and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.

The primary mechanism of vitamin D action is mediated through binding of either 1,25(OH)<sub>2</sub>D<sub>3</sub> (active form) or 25(OH)D (less active form) to the VDR, which is a member of the nuclear receptor superfamily of steroid and thyroid hormones with gene-regulatory and consequent anti-proliferative properties<sup>30,34</sup>. Binding of 1,25(OH)<sub>2</sub>D to the VDR (either in the cell nucleus or in the cytoplasm) promotes association of the VDR-1,25(OH)<sub>2</sub>D complex with the retinoid X receptor (RXR)<sup>21,30</sup>. The 1,25(OH)<sub>2</sub>D-VDR-RXR complex binds to vitamin D-response elements in DNA which operate to initiate gene transcription. Activation of the VDR by 1,25(OH)<sub>2</sub>D can restore or enhance proapoptotic effects in different cancer cells through transcriptional activation of bax and p-calpain, two effective proapoptotic proteins<sup>35,36</sup>. VDR-vitamin D activation also been demonstrated to increase mRNA expression of transforming growth factor, a potent anti-proliferative cytokine in normal and early stage cancer cells; superoxide dismutase, which may reduce oxidative stress-induced DNA damage and loss to DNA repair mechanisms that contribute to carcinogenesis and inflammatory cytokine production; as well as cyclin-dependent kinase (CDK) inhibitor p21, RBL2, RBLP6 and forkhead box O (FOXO) tumour suppressors that function to counteract MAPK-mediated phosphorylation and growth<sup>35,37-39</sup>.

VDR activation may also facilitate transcriptional repression of Bc1-2

Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)

**FOR CITATION PURPOSES:** Kingsley K, Bergman C, Keiserman M, Mobley C. Oral cancer risk and vitamin D status, intake and supplementation: A review. OA Cancer 2013 May 20;1(1):6.

and telomerase (pro-survival proteins), as well as CDK1 mRNA, which encodes a required protein for cell-cycle progression<sup>35,40</sup>. Suppression of vascular endothelial growth factor, responsible for angiogenesis, as well as the pro-inflammatory cyclooxygenase-2, was also observed<sup>41,42</sup>. In addition, 1,25(OH)<sub>2</sub>D may disrupt the function of  $\beta$ -catenin, the terminal mediator of Wnt signalling, which activates transcription of genes whose protein products (c-Myc and cyclin D1) control cell proliferation, as well as insulin-like growth factor-stimulated tumour growth<sup>21,43</sup>.

Despite these documented anti-cancer properties, some recent studies have demonstrated possible adverse effects of elevated 25(OH)D concentrations on cancer risk in prostate, breast, pancreas and oesophageal cancers, suggesting that these effects may depend on dose, timing and duration of exposure, as well as tissue-specific, lifestyle and genetic factors<sup>32,33</sup>. Although J- or U-shaped risk curves have been proposed to describe the noted associations in these studies, confounding factors present in the original studies are likely responsible for these findings<sup>31,32</sup>. For example, outcomes of intervention trials of supplemental vitamin D were inconclusive due to the lack of baseline vitamin D status reports of trial participants and consequent dose adequacy estimates<sup>31-33</sup>. This may suggest that studies focused on the dose administered, rather than their effect on alleviating deficiency, achieving adequacy or adding to pre-trial adequate serum levels, would have significantly affected the response curves and complicated the interpretation of trial outcomes.

One additional concern with these studies is a lack of control for confounding variables. Many cancers, including OPC, may exert effects on vitamin D metabolism by changing the availability of, or affecting the ability to bind to, the VDR. For example, there is some evidence that

specific cancers exhibit reduced VDR expression<sup>21,24,25</sup>. There is also evidence that Ras activation, common in many OPC cancers, may impair vitamin D-mediated transcription activity, while cytochrome p450 24 (CYP 24), the enzyme responsible for degradation of vitamin D metabolites, may be functionally active and up-regulated in many tumours<sup>44-46</sup>.

These tissue-specific characteristics may also explain the varying results obtained in experimental *in vitro* studies of 1,25(OH)<sub>2</sub>D on gene expression in several squamous cell carcinoma (SCC) head and neck cell lines (SCC4, SCC9, SC15 and SCC25), which demonstrated differing sensitivities among the cell lines ranging from complete cell-cycle arrest at G<sub>0</sub>/G<sub>1</sub> for SCC25 to only 50% inhibition of growth for SCC9<sup>47</sup>. Screening of more than 4,500 target genes yielded 38 up-regulated (at least 1.5 fold) target genes in SCC25 cells, including cell adhesion proteins, growth factors, cytoskeleton proteins, protein kinases, other intracellular signalling molecules and transcription factors previously implicated in control of cell-cycle growth and arrest. Although no change in expression of p27 or p53 mRNA levels was observed, and only a modest induction of p21 transcription was noted, another study using microarray technology to profile target gene regulation in SCC25 head and neck SCCs revealed 89 up-regulated and 63 down-regulated genes. The gene coding for cytochrome p450 24 [the protein that degrades 1,25(OH)<sub>2</sub>D<sub>3</sub>] exhibited the highest up-regulation of 196-fold<sup>48</sup>. This confirmed the findings of another study that found CYP24 mutations lowered oral cancer risk compared with wild type, after adjusting for age, gender, alcohol consumption and smoking status<sup>27</sup>.

### Conclusion

The primary goal of this critical review was to explore the research and evidence regarding the mechanisms through which vitamin D might

modulate the risk or progression of OPC. Although many clinical studies have suggested vitamin D status, intake and supplementation may have a significant influence on oral cancer risk, progression and mortality, growing epidemiologic evidence now suggests that dietary supplementation may not provide levels similar to UVB exposure. As work environments in the developing world are increasing indoors and the obesity crisis further limits physical activity and outdoor exposure, the impact and influence of vitamin D intake may become increasingly critical. In addition, although many studies have demonstrated the anti-tumour effects of vitamin D both *in vitro* and *in vivo*, new evidence suggests these effects are modulated by other factors, including tissue and tumour regulation of CYP24. These data combined suggest that more research is needed to examine the *in vitro* effects of vitamin D on OCP which include analyses of CYP27 and CYP24 activity and VDR expression, while clinical and *in vivo* studies should more closely examine the relationship between baseline vitamin D status and alleviating deficiency, achieving adequacy. This information may be useful to oral oncologists, oral health care providers and oral epidemiologists as they strive to improve patient health and outcomes.

### Abbreviations list

CDK, cyclin-dependent kinase; FOXO, forkhead box O; HPV, human papillomavirus; IU, international unit; MAPK, mitogen-activated protein kinase; OPC, oral and pharyngeal cancer; RXR, retinoid X receptor; SCC, squamous cell carcinoma; UV, ultraviolet; VDR, vitamin D receptor

### References

1. Saman DM. A review of the epidemiology of oral and pharyngeal carcinoma: update. *Head Neck Oncol.* 2012 Jan;4:1.
2. Curado MP, Hashibe M. Recent changes in the epidemiology of head and

- neck cancer. *Curr Opin Oncol.* 2009 May;21(3):194–200.
3. Petersen PE. Oral cancer prevention and control--the approach of the World Health Organization. *Oral Oncol.* 2009 Apr–May;45(4–5):454–60.
  4. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res.* 1998;489:3282–7.
  5. National Center for Health Statistics. Health, United States, 2009: With Special Feature on. Medical Technology. Hyattsville, MD. 2010;476–80.
  6. Swango PA. Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. *J Public Health Dent.* 1996 Fall;56(6):309–18.
  7. Shiboski CH, Shiboski SC, Silverman S Jr. Trends in oral cancer rates in the United States, 1973–1996. *Community Dent Oral Epidemiol.* 2000 Aug;28(4):249–56.
  8. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yanick R, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. *Cancer.* 2002 May;94(10):2766–92.
  9. Tomar SL. Trends and patterns of tobacco use in the United States. *Am J Med Sci.* 2003 Oct;326(4):248–54.
  10. Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. *Otolaryngol Head Neck Surg.* 2006 Sep;135(3):451–7.
  11. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. *Head Neck Pathol.* 2012 Jul;6(Suppl 1):S16–24.
  12. Kingsley K, O'Malley S, Chino M. Analysis of oral cancer epidemiology in the US reveals state-specific trends: implications for oral cancer prevention. *BMC Public Health.* 2008 Mar;8(1):87.
  13. Weglicki LS. Tobacco use assessment: what exactly is your patient using and why is it important to know? *Ethn Dis.* 2008 Summer;18(3 Suppl 3):S3–1.
  14. Bunnell A, Pettit N, Reddout N, Sharma K, O'Malley S, Chino M, Kingsley K. Analysis of primary risk factors for oral cancer from select US states with increasing rates. *Tob Induc Dis.* 2010 Feb;8:5.
  15. Lucenteforte E, Garavello W, Bosetti C, La Vecchia C. Dietary factors and oral and pharyngeal cancer risk. *Oral Oncol.* 2009 Jun;45(6):461–7.
  16. Garavello W, Lucenteforte E, Bosetti C, La Vecchia C. The role of foods and nutrients on oral and pharyngeal cancer risk. *Minerva Stomatologica.* 2009 Jan–Feb;58(1–2):25–34.
  17. Pelucchi C, Talamini R, Negri E, Levi F, Conti E, Franceschi S, et al. Folate intake and risk of oral and pharyngeal cancer. *Ann Oncol.* 2003 Nov;14(11):1677–81.
  18. Kingsley K. Potential effects of dietary folate supplementation on oral carcinogenesis, development and progression. *J Diet Suppl.* 2010 Mar;7(1):51–9.
  19. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. *Endocrinol Metab Clin North Am.* 2010 Jun;39(2):401–18.
  20. Giovannucci E. Vitamin D status and cancer incidence and mortality. *Adv Exp Med Biol.* 2008;624:31–42.
  21. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. *Biochem J.* 2012 Jan;441(1):61–76.
  22. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. *Eu J Cancer.* 2010 Aug;46(12):2196–205.
  23. Bektas-Kayhan K, Unur M, Yaylim-Eraltan I, Ergen HA, Toptas B, Hafiz G, et al. Association of vitamin D receptor Taq I polymorphism and susceptibility to oral squamous cell carcinoma. In vivo (Athens, Greece). 2010 Sep–Oct;24(5):755–9.
  24. Ha PK, Chang SS, Glazer CA, Califano JA, Sidransky D. Molecular techniques and genetic alterations in head and neck cancer. *Oral Oncol.* 2009 Apr–May;45(4–5):335–9.
  25. Cadoni G, Boccia S, Petrelli L, Di Gianantonio P, Arzani D, Giorgio A, et al. A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism. *Acta Otorhinolaryngol Ital.* 2012 Feb;32(1):1–11.
  26. Chen C, Mendez E, Houck J, et al. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2008 Aug;17(8):2152–62.
  27. Zeljic K, Supic G, Stamenkovic Radak M, Jovic N, Kozomara R, Magic Z. Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. *J Oral Pathol Med.* 2012 Nov;41(10):779–87.
  28. Hama T, Norizoe C, Suga H, Mimura T, Kato T, Moriyama H, et al. Prognostic Significance of Vitamin D Receptor Polymorphisms in Head and Neck Squamous Cell Carcinoma. *PLoS One.* 2011;6(12):e2.
  29. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington (DC): National Academies Press (US); 1997.
  30. Shils ME, Shike M. Modern nutrition in health and disease. Lippincott Williams & Wilkins; 2006.
  31. Heaney RP. Vitamin D--baseline status and effective dose. *N Engl J Med.* 2012 Jul;367(1):77–8.
  32. Grant WB. Ecological studies of the UVB-vitamin D-cancer hypothesis. *Anticancer Res.* 2012 Jan;32(1):223–36.
  33. Toner CD, Davis CD, Milner JA. The vitamin D and cancer conundrum: aiming at a moving target. *J Am Diet Assoc.* 2010 Oct;110(10):1492–500.
  34. Lou YR, Molnar F, Perakyla M, Qiao S, Kalueff AV, St-Arnaud R, et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. *J Steroid Biochem Mol Biol.* 2010 Feb;118(3):162–70.
  35. Kizildag S, Ates H, Kizildag S. Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. *Ann Hematol.* 2010 Jan;89(1):1–7.
  36. Fedirko V, Bostick RM, Flanders WD, Long Q, Shaikat A, Rutherford RE, et al. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. *Cancer Prev Res (Phila).* 2009 Mar;2(3):213–23.
  37. Krueger C, Hoffmann FM. Identification of retinoic acid in a high content screen for agents that overcome the anti-myogenic effect of TGF-beta-1. *PLoS One.* 2010 Nov;5(11):e15511.
  38. Ravid A, Koren R. The role of reactive oxygen species in the anticancer activity of vitamin D. *Recent Results Cancer Res.* 2003;164:357–67.
  39. An BS, Tavera-Mendoza LE, Dimitrov V, Wang X, Calderon MR, Wang HJ, et al. Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. *Mol Cell Biol.* 2010 Oct;30(20):4890–900.
  40. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits

Licensee OA Publishing London 2013. Creative Commons Attribution License (CC-BY)

**FOR CITATION PURPOSES:** Kingsley K, Bergman C, Keiserman M, Mobley C. Oral cancer risk and vitamin D status, intake and supplementation: A review. *OA Cancer* 2013 May 20;1(1):6.

proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. *Fertil Steril.* 2011 Jan;95(1):247–53.

41. Walker DD, Reeves TD, de Costa AM, Schuyler C, Young MR. Immunological modulation by  $1\alpha,25$ -dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck. *Cytokine.* 2012 Jun;58(3):448–54.

42. McCarty MF. Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention. *Med Hypotheses.* 2012 Jan;78(1):45–57.

43. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like

growth factor binding protein-3. *J Mol Endocrinol.* 1998 Feb;20(1):157–62.

44. Luo W, Hershberger PA, Trump DL, Johnson CS. 24-Hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics. *J Steroid Biochem Mol Biol.* 2013 Jul;S0960-0760(12):00200-2.

45. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. *JAMA.* 2012 Nov;308(18):1898–905.

46. Goltzman D, White J, Kremer R. Studies of the effects of  $1,25$ -dihydroxyvitamin D on skeletal and calcium homeostasis and on inhibition of tumor cell growth. *J Steroid Biochem Mol Biol.* 2001 Jan–Mar;76(1–5):43–7.

47. Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, et al. Regulation of gene expression by  $1\alpha,25$ -dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. *Mol Endocrinol (Baltimore, Md.).* 2001 Jul;15(7):1127–39.

48. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. *Molecular Endocrinol (Baltimore, Md.).* 2002 Jun;6(6):1243–56.

49. Palacios C, Joshipura K, Willett W. Nutrition and health: guidelines for dental practitioners. *Oral Dis.* 2009 Sep;15(6):369–81.